It's Official: Weight Loss Pill Has Been Approved for the UK

For the millions of people living with obesity in the UK who have been curious about weight loss treatment but put off by needle anxiety, this is a genuinely game-changing development. No injections. No weekly pen. Just a daily tablet — backed by the same science that has already transformed outcomes with injections.

It has been one of the most anticipated moments in UK weight loss medicine — and on 11 June 2026, it finally arrived. The Medicines and Healthcare products Regulatory Agency (MHRA) formally approved the Wegovy pill — an oral, once-daily tablet version of semaglutide — for weight management in the United Kingdom. Critically, the UK is the first country in Europe to grant this approval, underlining the MHRA's increasingly independent and proactive role in global medicines regulation since Brexit.

At Happy Pharmacy, we have been following this closely. Here is the full picture — what the approval means, who is eligible, what the dosing looks like, and what you can do right now.

What the MHRA Has Approved — and What It Means

The MHRA's approval covers semaglutide tablets (Wegovy, Novo Nordisk) for use alongside a reduced-calorie diet and increased physical activity in adults with:

•       A BMI of 30 or above (obesity), or

•       A BMI of 27–30 (overweight) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or raised cholesterol.

This is the same eligibility criteria as the injectable Wegovy, meaning that patients who already qualify for the injection would also qualify for the pill. Importantly, the MHRA has also confirmed that patients currently being treated privately with the 2.4 mg semaglutide injection once weekly can be transitioned directly to the 25 mg tablet once daily — a significant convenience for those already on their weight loss journey.

The Wegovy pill is the third regulatory authority in the world to license this medicine, after the US FDA (December 2025) and the UAE. As the first approval in Europe, the UK is setting the regulatory benchmark ahead of any European Medicines Agency (EMA) decision.

How Do You Take It? The Approved Dosing Schedule

One of the most important things to understand about the Wegovy pill is that it works on a gradual dose escalation schedule — starting low and building up over several months. This is the same approach used with the injectable version and is designed to minimise side effects while the body adjusts.

Minimum of one month at each dose level before escalating. Maximum dose: 25 mg once daily.

The MHRA has confirmed that the tablet must be taken on an empty stomach — after fasting for at least 8 hours — and swallowed whole with only a small sip of plain water. Crucially, food, drink, and other medications must be avoided for at least 30 minutes after taking it. This fasting requirement is essential: food or drink consumed too soon can significantly reduce how much semaglutide is absorbed through the stomach lining, making the tablet less effective.

For most people, the simplest approach is to take the pill immediately upon waking, then go about your morning routine for half an hour before having breakfast. For those with busy mornings, this is an important routine to plan around from day one.

What Does the Trial Data Show?

The MHRA approval is based on data from the OASIS 4 phase III trial, which was published in the New England Journal of Medicine in September 2025. This was a 64-week, randomised, double-blind, placebo-controlled trial of 307 adults with obesity or overweight who also received lifestyle guidance alongside their medication.

These results are comparable to the injectable Wegovy at its 2.4 mg dose — a critically important finding. It confirms that the tablet does not meaningfully underperform the injection in terms of weight loss outcomes. For anyone who has previously avoided treatment due to needle anxiety, this means they no longer have to weigh up efficacy against discomfort. The pill delivers.

A further analysis of OASIS 4 data showed that participants also experienced significant improvements in blood pressure, HbA1c, triglycerides, waist circumference, and overall quality-of-life measures — demonstrating that the benefits of the Wegovy pill extend well beyond the number on the scales.

Sources: OASIS 4 (NEJM, 2025); STEP 1 (NEJM, 2021); SURMOUNT-1 (NEJM, 2022). All values represent mean % body weight reduction vs baseline.

Is the Wegovy Pill Safe?

The safety profile of the Wegovy pill is well-characterised and consistent with what we already know from injectable GLP-1 medications. The most commonly reported side effects in OASIS 4 were gastrointestinal — nausea, vomiting, diarrhoea, and constipation — which affected the majority of participants taking the active medicine. However, these effects were typically mild to moderate and tended to improve over time as the body adjusted during the dose escalation phase.

Only 7% of participants discontinued treatment due to adverse events — virtually the same rate as the placebo group (6%). This is a reassuring finding and consistent with the safety profile of the Wegovy injection. The MHRA noted that the benefit-risk balance clearly supports approval, and the MHRA Yellow Card scheme remains in place for any patients who experience unexpected side effects following launch.

As with all medicines, the Wegovy pill should only be prescribed following a thorough clinical assessment that includes independent verification of weight, height, BMI, and relevant medical history — as required under the GPhC's February 2025 guidance on high-risk medicines. At Happy Pharmacy, this is the standard we have always worked to.

Pill vs. Injection: How Do They Compare?

Now that both forms of Wegovy are MHRA-approved in the UK, the choice between pill and injection comes down to individual preference, lifestyle, and clinical suitability. Here is the full comparison.

It is worth noting that Mounjaro (tirzepatide) — which targets both GLP-1 and GIP receptors — continues to produce the strongest weight loss results of any MHRA-approved treatment in the UK, with mean losses of up to 20.9% in the SURMOUNT-1 trial. For those who are comfortable with injections and want maximum efficacy, Mounjaro remains the leading option. The Wegovy pill, however, fills a crucial gap: it opens up clinically meaningful weight loss treatment to everyone who has previously said no to needles.

When Can You Actually Get It?

MHRA approval and commercial availability are two separate steps. As of mid-June 2026, the Wegovy pill has been approved but is not yet commercially available in the UK. Novo Nordisk has confirmed plans to launch in select markets during the second half of 2026, and UK pharmacies are expected to receive stock within this window.

NHS access will follow a separate review by NICE — the National Institute for Health and Care Excellence — which will assess clinical and cost-effectiveness before issuing prescribing guidance. This process typically takes 6–9 months following MHRA approval, meaning NHS availability is unlikely before late 2027.

The Bottom Line

The MHRA's approval of the Wegovy pill on 11 June 2026 is a watershed moment for weight loss medicine in the UK. For the first time, adults living with obesity or overweight can access a clinically proven GLP-1 treatment in tablet form — without a single injection. The UK has led Europe on this approval, and the clinical evidence behind the pill is robust and compelling.

Whether you are ready to start your weight loss journey now with a Wegovy injection or Mounjaro, or you are keen to begin with the pill as soon as it becomes commercially available, the key is accessing treatment through a trusted, regulated provider who will support you every step of the way.

At Happy Pharmacy, we offer a personal, regulated online service that puts your safety and results at the centre of everything we do. To find out which weight loss treatment is right for you today, visit or Weight Loss Page

References

1. MHRA. First GLP-1 tablet for weight loss approved in the UK. 11 June 2026. Available at: gov.uk

2. The Pharmaceutical Journal. MHRA approves semaglutide oral tablets for weight loss. June 2026. Available at: pharmaceutical-journal.com

3. Novo Nordisk press release. Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK. 11 June 2026. Available at: biospace.com

4. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine. 2025. NCT05564117. Available at: pubmed.ncbi.nlm.nih.gov/40934115/

5. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989–1002. Available at: nejm.org

6. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216. Available at: nejm.org